When the trial of rivaroxaban compared with enoxaparin 30 mg twice daily (RECORD4; n = 12,729) was included in a pooled analysis of all four RECORD trials, rivaroxaban was associated with a significantly lower incidence of symptomatic VTE plus all-cause mortality than enoxaparin on treatment (Table 3) , with no significant differences between treatments in terms of major bleeding, major plus non-major clinically relevant bleeding, or any bleeding [42].
should read:
Through population pharmacokinetic analysis the expected peak and trough plasma concentrations for rivaroxaban 20 mg in the long-term treatment of VTE are 270 lg/L (189-419 lg/L) and 26 lg/L (6-87 lg/L), respectively. For patients with atrial fibrillation and creatinine clearance (CrCl) C50 mL/min the concurrent values are 249 lg/L (184-343 lg/mL) and 44 lg/L (12-137 lg/L) [22] .
Page 1590, section 2.3, paragraph 1, lines 4-6: The following sentence, which previously read:
Without food, the bioavailability of a 20-mg dose of rivaroxaban was 66 % and the AUC was 1,447 lgÁh/L.
Without food, the bioavailability of a 20-mg dose of rivaroxaban was 66 % and the AUC was 1,477 lgÁh/L.
Page 1592, right-hand column, lines 11-17, over to page 1593, lines 1-3: The following sentence, which previously read:
When the trial of rivaroxaban compared with enoxaparin 30 mg twice daily (RECORD4; n = 12,729) was included in a pooled analysis of all four RECORD trials, rivaroxaban was associated with a significantly lower incidence of symptomatic VTE plus all-cause mortality than enoxaparin on treatment (Table 3) , with no significant differences between treatments in terms of major bleeding, major plus non-major clinically relevant bleeding, or any bleeding [42] .
When the trial of rivaroxaban compared with enoxaparin 30 mg twice daily (RECORD4; n = 3,148) was included in a pooled analysis of all four RECORD trials (n = 12,729), rivaroxaban was associated with a significantly lower incidence of symptomatic VTE plus all-cause mortality than enoxaparin on treatment (Table 3) , with no significant differences between treatments in terms of major bleeding, major plus non-major clinically relevant bleeding, or any bleeding [42] .
